Heska Corp  

(Public, NASDAQ:HSKA)   Watch this stock  
Find more results for Jason Riley´┐Ż
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 10.38 - 31.87
Open     -
Vol / Avg. 0.00/59,809.00
Mkt cap 195.05M
P/E 65.28
Div/yield     -
EPS 0.46
Shares 6.50M
Beta 0.50
Inst. own 46%
Jul 28, 2015
Q2 2015 Heska Corp Earnings Release (Estimated) Add to calendar
May 7, 2015
Q1 2015 Heska Corp Earnings Call
May 7, 2015
Q1 2015 Heska Corp Earnings Release
Mar 5, 2015
Q4 2014 Heska Corp Earnings Call
Mar 5, 2015
Q4 2014 Heska Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 2.55% 1.78%
Operating margin 4.46% 3.24%
EBITD margin - 7.37%
Return on average assets 2.37% 1.68%
Return on average equity 4.47% 5.19%
Employees 301 -
CDP Score - -


3760 Rocky Mountain Avenue
United States - Map
+1-970-4937272 (Phone)
+1-970-6193003 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company is focused on the canine and feline companion animal health markets. It operates in two segments: Core Companion Animal Health and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment (CCA) includes diagnostic instruments and supplies, as well as single use diagnostic and other tests, vaccines and pharmaceuticals, primarily for canine and feline use. These products are sold directly by the Company as well as through independent third-party distributors and through other distribution relationships. The Other Vaccines, Pharmaceuticals and Products segment (OVP) includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals and fish. All OVP products are sold by third parties under third party labels.

Officers and directors

Robert B Grieve Executive Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Kevin S. Wilson President, Chief Executive Officer
Age: 43
Bio & Compensation  - Reuters
Jason A. Napolitano Chief Financial Officer, Executive Vice President, Secretary
Age: 46
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael J. McGinley Ph.D. President - Biologicals & Pharmaceuticals
Age: 54
Bio & Compensation  - Reuters
Steven M. Asakowicz Executive Vice President - Companion Animal Health Sales
Age: 49
Bio & Compensation  - Reuters
Rodney A. Lippincott Executive Vice President - Companion Animal Health Sales
Age: 41
Bio & Compensation  - Reuters
Nancy Wisnewski Ph.D. Executive Vice President - Product Development and Customer Support
Age: 51
Bio & Compensation  - Reuters
Sharon L. Riley Lead Director
Age: 54
Bio & Compensation  - Reuters
William A. Aylesworth Director
Age: 72
Bio & Compensation  - Reuters
David E. Sveen Ph.D. Director
Age: 58
Bio & Compensation  - Reuters